{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:16:08Z","timestamp":1792001768141,"version":"4.4.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018778","name":"Al-Azhar University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018778","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Alzheimer\u2019s disease (AD) is a neurodegenerative disorder characterized by progressive deterioration in cognitive functions. It represents a global health concern with increasing prevalence and devastating outcomes for the quality of life that could ultimately lead to death. AD is associated with deposition of \u03b2-amyloid (A\u03b2) plaques and intracellular buildup of tau proteins forming neurofibrillary tangles (NFTs), which are the main characteristics for AD brain tissues. Approved AD therapy is based mainly on symptomatic relief, and conventional medicaments often fail due to either low bioavailability, limited solubility, or failure to cross blood\u2013brain barrier (BBB). The complexity in AD pathophysiology opens windows for many therapeutic options. So, lecanemab was recently approved by FDA as the first disease-modifying therapy. However, drug delivery to the brain remains challenging due to the nature of BBB. Hence, more extensive research is essential to develop disease-modifying therapies and also to find drug delivery strategies to ensure simplified administration and successful brain delivery. This review article summarizes AD pathogenesis with the corresponding treatment targets. It emphasizes innovative drug delivery strategies and novel formulation approaches to deliver medicines across BBB. The use of recent advancements in drug delivery to deliver medicaments across BBB are highlighted, with focus given to novel drug delivery systems and formulation of nanoparticles for brain targeting. The use of nutraceuticals, gene therapy, and stem cell therapy are is covered.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1208\/s12249-025-03316-z","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:33:01Z","timestamp":1768509181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Challenges and Opportunities of Drug Delivery for Treatment of Alzheimer\u2019s Disease"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5275-0810","authenticated-orcid":false,"given":"Marwa Adel","family":"Abd El-Fattah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"3316_CR1","doi-asserted-by":"publisher","first-page":"102481","DOI":"10.1016\/j.arr.2024.102481","volume":"101","author":"PT Kamatham","year":"2024","unstructured":"Kamatham PT, Shukla R, Khatri DK, Vora LK. Pathogenesis, diagnostics, and therapeutics for Alzheimer\u2019s disease: breaking the memory barrier. Ageing Res Rev. 2024;101:102481. https:\/\/doi.org\/10.1016\/j.arr.2024.102481.","journal-title":"Ageing Res Rev"},{"key":"3316_CR2","doi-asserted-by":"publisher","unstructured":"Vitali F, Branigan GL, Brinton RD. Preventing Alzheimer\u2019s disease within reach by 2025: targeted-risk-AD-prevention (TRAP) strategy. Alzheimers Dement Transl Res Clin Interv [Internet]. John Wiley & Sons, Ltd; 2021 [cited 2025 Aug 21];7:e12190. https:\/\/doi.org\/10.1002\/trc2.12190.","DOI":"10.1002\/trc2.12190"},{"key":"3316_CR3","doi-asserted-by":"publisher","unstructured":"Hassan NA, Alshamari AK, Hassan AA, Elharrif MG, Alhajri AM, Sattam M, et al. Advances on therapeutic strategies for Alzheimer\u2019s disease: from medicinal plant to nanotechnology. Molecules. 2022;27. https:\/\/doi.org\/10.3390\/molecules27154839.","DOI":"10.3390\/molecules27154839"},{"key":"3316_CR4","doi-asserted-by":"publisher","unstructured":"Hou M, Yang L. Trends and forecasts of the prevalence and mortality of Alzheimer\u2019s disease and other dementias in China. Front Public Health [Internet]. 2025;Volume 13\u20132025. https:\/\/doi.org\/10.3389\/fpubh.2025.1616232.","DOI":"10.3389\/fpubh.2025.1616232"},{"key":"3316_CR5","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-025-03564-3","volume":"31","author":"S Moutinho","year":"2025","unstructured":"Moutinho S. Women twice as likely to develop Alzheimer\u2019s disease as men \u2014 but scientists do not know why. Nat Med. 2025;31:704\u20137. https:\/\/doi.org\/10.1038\/s41591-025-03564-3.","journal-title":"Nat Med"},{"key":"3316_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40120-024-00695-6","volume":"14","author":"H Zhang","year":"2025","unstructured":"Zhang H, Tahami Monfared AA, Zhang Q, Honig LS. Incidence and prevalence of Alzheimer\u2019s disease in Medicare beneficiaries. Neurol Ther [Internet]. 2025;14:319\u201333. https:\/\/doi.org\/10.1007\/s40120-024-00695-6.","journal-title":"Neurol Ther [Internet]"},{"key":"3316_CR7","doi-asserted-by":"publisher","unstructured":"Namrouti A, Desamour P, Marquez A, Lorenzen C, Cervantes O, Hodges TB, et al. Atypical Early Onset Alzheimer\u2019s Disease in a Young Female: A Case Report. Cureus [Internet]. Cureus, Inc.; 2025;17:e78082.  https:\/\/doi.org\/10.7759\/cureus.78082.","DOI":"10.7759\/cureus.78082"},{"key":"3316_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41582-023-00789-z","volume":"19","author":"C Reitz","year":"2023","unstructured":"Reitz C, Pericak-Vance MA, Foroud T, Mayeux R. A global view of the genetic basis of Alzheimer disease. Nat Rev Neurol. 2023;19:261\u201377. https:\/\/doi.org\/10.1038\/s41582-023-00789-z.","journal-title":"Nat Rev Neurol"},{"key":"3316_CR9","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.1038\/s41598-025-89899-w","volume":"15","author":"F Amiri","year":"2025","unstructured":"Amiri F, Safiri S, Shamekh A, Ebrahimi A, Sullman MJM, Kolahi A-A. Prevalence, deaths and disability-adjusted life years due to Alzheimer\u2019s disease and other dementias in Middle East and North Africa, 1990\u20132021. Sci Rep [Internet]. 2025;15:7058. https:\/\/doi.org\/10.1038\/s41598-025-89899-w.","journal-title":"Sci Rep [Internet]"},{"key":"3316_CR10","doi-asserted-by":"publisher","unstructured":"Aiello AE, Momkus J, Stebbins RC, Zhang YS, Martin CL, Yang YC, et al. Risk factors for Alzheimer\u2019s disease and cognitive function before middle age in a U.S. representative population-based study. Lancet Reg Health \u2013 Am [Internet]. Elsevier; 2025 [cited 2025 Aug 21];45. https:\/\/doi.org\/10.1016\/j.lana.2025.101087.","DOI":"10.1016\/j.lana.2025.101087"},{"key":"3316_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","volume":"367","author":"B Singh","year":"2024","unstructured":"Singh B, Day CM, Abdella S, Garg S. Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management. J Control Release. 2024;367:402\u201324. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.047.","journal-title":"J Control Release"},{"key":"3316_CR12","doi-asserted-by":"publisher","unstructured":"Dhingra H, Choudhari SG. Alzheimer\u2019s disease: understanding its novel drug delivery systems and treatments. Cureus [Internet]. Cureus, Inc.; 2022;14:e31394. https:\/\/doi.org\/10.7759\/cureus.31394.","DOI":"10.7759\/cureus.31394"},{"key":"3316_CR13","doi-asserted-by":"publisher","unstructured":"Passeri E, Elkhoury K, Morsink M, Broersen K, Linder M, Tamayol A, et al. Alzheimer\u2019s disease: treatment strategies and their limitations. Int J Mol Sci. 2022;23. https:\/\/doi.org\/10.3390\/ijms232213954.","DOI":"10.3390\/ijms232213954"},{"key":"3316_CR14","doi-asserted-by":"publisher","unstructured":"Fan L, Mao C, Hu X, Zhang S, Yang Z, Hu Z, et al. New Insights into the pathogenesis of Alzheimer\u2019s disease. Front Neurol [Internet]. 2020;Volume 10\u20132019. https:\/\/doi.org\/10.3389\/fneur.2019.01312.","DOI":"10.3389\/fneur.2019.01312"},{"key":"3316_CR15","doi-asserted-by":"publisher","unstructured":"Chen Z-R, Huang J-B, Yang S-L, Hong F-F. Role of cholinergic signaling in Alzheimer\u2019s disease. Molecules. 2022;27. https:\/\/doi.org\/10.3390\/molecules27061816.","DOI":"10.3390\/molecules27061816"},{"key":"3316_CR16","doi-asserted-by":"publisher","unstructured":"Dominguez-Gortaire J, Ruiz A, Porto-Pazos AB, Rodriguez-Yanez S, Cedron F. Alzheimer\u2019s disease: exploring pathophysiological hypotheses and the role of machine learning in drug discovery. Int J Mol Sci. 2025;26. https:\/\/doi.org\/10.3390\/ijms26031004.","DOI":"10.3390\/ijms26031004"},{"key":"3316_CR17","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.neurobiolaging.2021.07.014","volume":"107","author":"A Ionescu-Tucker","year":"2021","unstructured":"Ionescu-Tucker A, Cotman CW. Emerging roles of oxidative stress in brain aging and Alzheimer\u2019s disease. Neurobiol Aging. 2021;107:86\u201395. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2021.07.014.","journal-title":"Neurobiol Aging"},{"key":"3316_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-020-00189-z","volume":"9","author":"L Wang","year":"2020","unstructured":"Wang L, Yin Y-L, Liu X-Z, Shen P, Zheng Y-G, Lan X-R, et al. Current understanding of metal ions in the pathogenesis of Alzheimer\u2019s disease. Transl Neurodegener. 2020;9: 10. https:\/\/doi.org\/10.1186\/s40035-020-00189-z.","journal-title":"Transl Neurodegener"},{"key":"3316_CR19","doi-asserted-by":"publisher","unstructured":"Blaikie L, Kay G, Kong Thoo Lin P.  Current and emerging therapeutic targets of Alzheimer\u2019s disease for the design of multi-target directed ligands. MedChemComm [Internet]. Royal Soc Chem. 2019;10:2052\u201372. https:\/\/doi.org\/10.1039\/C9MD00337A.","DOI":"10.1039\/C9MD00337A"},{"key":"3316_CR20","doi-asserted-by":"publisher","unstructured":"Liu J, Chang L, Song Y, Li H, Wu Y. The role of NMDA receptors in alzheimer\u2019s disease. Front Neurosci [Internet]. 2019;Volume 13\u20132019. https:\/\/doi.org\/10.3389\/fnins.2019.00043.","DOI":"10.3389\/fnins.2019.00043"},{"key":"3316_CR21","doi-asserted-by":"publisher","first-page":"103371","DOI":"10.1016\/j.gerinurse.2025.05.010","volume":"64","author":"Z Sadruddin","year":"2025","unstructured":"Sadruddin Z, Harris K, Bilsborough E, Sciba L, Vargas AF, Shyer M, et al. Anti-amyloid immunotherapies for Alzheimer\u2019s disease: administration, side effects, and overall framework. Geriatr Nurs. 2025;64:103371. https:\/\/doi.org\/10.1016\/j.gerinurse.2025.05.010.","journal-title":"Geriatr Nurs"},{"key":"3316_CR22","doi-asserted-by":"publisher","unstructured":"Peng Y, Jin H, Xue Y, Chen Q, Yao S, Du M, et al. Current and future therapeutic strategies for Alzheimer\u2019s disease: an overview of drug development bottlenecks. Front Aging Neurosci [Internet]. 2023;15\u20132023. https:\/\/doi.org\/10.3389\/fnagi.2023.1206572.","DOI":"10.3389\/fnagi.2023.1206572"},{"key":"3316_CR23","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.bbadis.2011.11.005","volume":"1822","author":"AG Vlassenko","year":"2012","unstructured":"Vlassenko AG, Benzinger TLS, Morris JC. PET amyloid-beta imaging in preclinical Alzheimer\u2019s disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2012;1822:370\u20139. https:\/\/doi.org\/10.1016\/j.bbadis.2011.11.005.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"3316_CR24","doi-asserted-by":"publisher","unstructured":"Ortner M, Pasquini L, Barat M, Alexopoulos P, Grimmer T, F\u00f6rster S, et al. progressively disrupted intrinsic functional connectivity of basolateral amygdala in very early Alzheimer\u2019s disease. Front Neurol [Internet]. 2016;Volume 7\u20132016. https:\/\/doi.org\/10.3389\/fneur.2016.00132.","DOI":"10.3389\/fneur.2016.00132"},{"key":"3316_CR25","doi-asserted-by":"publisher","first-page":"105557","DOI":"10.1016\/j.ebiom.2025.105557","volume":"112","author":"RN Taddei","year":"2025","unstructured":"Taddei RN, E. Duff K. Synapse vulnerability and resilience underlying Alzheimer\u2019s disease. EBioMedicine. 2025;112:105557. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105557.","journal-title":"EBioMedicine"},{"issue":"2","key":"3316_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/joim.13244","volume":"290","author":"JL Liss","year":"2021","unstructured":"Liss JL, Seleri Assun\u00e7\u00e3o S, Cummings J, Atri A, Geldmacher DS, Candela SF, et al. Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer\u2019s disease (MCI and dementia) in primary care: a review and synthesis. J Intern Med. 2021;290(2):310\u201334. https:\/\/doi.org\/10.1111\/joim.13244.","journal-title":"J Intern Med"},{"key":"3316_CR27","doi-asserted-by":"publisher","unstructured":"Wu C-K, Fuh J-L. A 2025 update on treatment strategies for the Alzheimer\u2019s disease spectrum. J Chin Med Assoc [Internet]. 2025;88. https:\/\/doi.org\/10.1097\/JCMA.0000000000001252.","DOI":"10.1097\/JCMA.0000000000001252"},{"key":"3316_CR28","doi-asserted-by":"publisher","unstructured":"Breijyeh Z, Karaman R. Comprehensive review on Alzheimer\u2019s disease: causes and treatment. Molecules. 2020;25. https:\/\/doi.org\/10.3390\/molecules25245789.","DOI":"10.3390\/molecules25245789"},{"key":"3316_CR29","doi-asserted-by":"publisher","first-page":"108352","DOI":"10.1016\/j.neuropharm.2020.108352","volume":"190","author":"G Marucci","year":"2021","unstructured":"Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer\u2019s disease. Neuropharmacology. 2021;190:108352. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108352.","journal-title":"Neuropharmacology"},{"key":"3316_CR30","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.bbamem.2019.03.014","volume":"1861","author":"P Zambrano","year":"2019","unstructured":"Zambrano P, Suwalsky M, Jemiola-Rzeminska M, Strzalka K, Sep\u00falveda B, Gallardo MJ, et al. The acetylcholinesterase (AChE) inhibitor and anti-Alzheimer drug donepezil interacts with human erythrocytes. Biochimica et Biophysica Acta (BBA) - Biomembranes. 2019;1861:1078\u201385. https:\/\/doi.org\/10.1016\/j.bbamem.2019.03.014.","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes"},{"key":"3316_CR31","doi-asserted-by":"publisher","unstructured":"Yiannopoulou KG, Papageorgiou SG. Current and Future Treatments in Alzheimer Disease: An Update. J Cent Nerv Syst Dis [Internet].  2020;12:1179573520907397. https:\/\/doi.org\/10.1177\/1179573520907397. SAGE Publications Ltd STM.","DOI":"10.1177\/1179573520907397"},{"key":"3316_CR32","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7861\/clinmedicine.16-3-247","volume":"16","author":"R Briggs","year":"2016","unstructured":"Briggs R, Kennelly SP, O\u2019Neill D. Drug treatments in Alzheimer\u2019s disease. Clin Med. 2016;16:247\u201353. https:\/\/doi.org\/10.7861\/clinmedicine.16-3-247.","journal-title":"Clin Med"},{"key":"3316_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ibneur.2025.05.016","volume":"19","author":"S Hajihosseini","year":"2025","unstructured":"Hajihosseini S, Zakavi SA, Farrokhi Z, Amanzadeh M, Panahi P, Mahram M, et al. A meta-analysis update evaluating the treatment effects of donepezil alone versus donepezil combined with memantine for Alzheimer\u2019s disease. IBRO Neurosci Rep. 2025;19:72\u201382. https:\/\/doi.org\/10.1016\/j.ibneur.2025.05.016.","journal-title":"IBRO Neurosci Rep"},{"key":"3316_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W. Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther. 2023;8: 248. https:\/\/doi.org\/10.1038\/s41392-023-01484-7.","journal-title":"Signal Transduct Target Ther"},{"key":"3316_CR35","doi-asserted-by":"crossref","unstructured":"Siddiqui AJ, Badraoui R, Jahan S, Alshahrani MM, Siddiqui MA, Khan A, et al. Targeting NMDA receptor in Alzheimer\u2019s disease: identifying novel inhibitors using computational approaches. Front Pharmacol [Internet]. 2023;14\u20132023. https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2023.1208968.","DOI":"10.3389\/fphar.2023.1208968"},{"key":"3316_CR36","doi-asserted-by":"publisher","unstructured":"Beshir SA, Hussain N, Menon VB, Al Haddad AHI, Al Zeer RAK, Elnour AA, et al. Advancements and challenges in antiamyloid therapy for Alzheimer\u2019s disease: a comprehensive review. Int J Alzheimers Dis [Internet]. John Wiley & Sons, Ltd; 2024 [cited 2025 Aug 23];2024:2052142.https:\/\/doi.org\/10.1155\/2024\/2052142.","DOI":"10.1155\/2024\/2052142"},{"key":"3316_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s41983-023-00682-y","volume":"59","author":"AZ Nourelden","year":"2023","unstructured":"Nourelden AZ, Kamal I, Tawfik AG, Hagrass AI, Fathallah AH, Zaazouee MS. Safety and efficacy of sodium oligomannate in patients with Alzheimer\u2019s disease: a systematic review and meta-analysis. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2023;59: 82. https:\/\/doi.org\/10.1186\/s41983-023-00682-y.","journal-title":"The Egyptian Journal of Neurology, Psychiatry and Neurosurgery"},{"key":"3316_CR38","doi-asserted-by":"publisher","first-page":"115406","DOI":"10.1016\/j.biopha.2023.115406","volume":"166","author":"J Liu","year":"2023","unstructured":"Liu J, Li T, Zhong G, Pan Y, Gao M, Su S, et al. Exploring the therapeutic potential of natural compounds for Alzheimer\u2019s disease: mechanisms of action and pharmacological properties. Biomed Pharmacother. 2023;166:115406. https:\/\/doi.org\/10.1016\/j.biopha.2023.115406.","journal-title":"Biomed Pharmacother"},{"key":"3316_CR39","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41598-021-81042-9","volume":"11","author":"MD Fraser","year":"2021","unstructured":"Fraser MD, Vallin HE, Davies JRT, Rowlands GE, Chang X. Integrating Narcissus-derived galanthamine production into traditional upland farming systems. Sci Rep [Internet]. 2021;11:1389. https:\/\/doi.org\/10.1038\/s41598-021-81042-9.","journal-title":"Sci Rep [Internet]"},{"key":"3316_CR40","doi-asserted-by":"publisher","unstructured":"Fumia A, Cicero N, Gitto M, Nicosia N, Alesci A. Role of nutraceuticals on neurodegenerative diseases: neuroprotective and immunomodulant activity. Nat Prod Res [Internet]. Taylor & Francis; 2022;36:5916\u201333. https:\/\/doi.org\/10.1080\/14786419.2021.2020265.","DOI":"10.1080\/14786419.2021.2020265"},{"key":"3316_CR41","doi-asserted-by":"publisher","first-page":"9833","DOI":"10.1007\/s00210-024-03231-3","volume":"397","author":"M Ermi\u015f","year":"2024","unstructured":"Ermi\u015f M, \u00c7iftci G. Role of curcumin on beta-amyloid protein, tau protein, and biochemical and oxidative changes in streptozotocin-induced diabetic rats. Naunyn Schmiedebergs Arch Pharmacol. 2024;397:9833\u201344. https:\/\/doi.org\/10.1007\/s00210-024-03231-3.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"3316_CR42","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.1208\/s12249-018-1180-3","volume":"19","author":"SM Etman","year":"2018","unstructured":"Etman SM, Elnaggar YSR, Abdelmonsif DA, Abdallah OY. Oral brain-targeted microemulsion for enhanced piperine delivery in Alzheimer\u2019s disease therapy: in vitro appraisal, in vivo activity, and nanotoxicity. AAPS PharmSciTech [Internet]. 2018;19:3698\u2013711. https:\/\/doi.org\/10.1208\/s12249-018-1180-3.","journal-title":"AAPS PharmSciTech [Internet]"},{"key":"3316_CR43","doi-asserted-by":"crossref","unstructured":"Adnan M, Siddiqui AJ, Bardakci F, Surti M, Badraoui R, Patel M. Neuroprotective potential of quercetin in Alzheimer\u2019s disease: targeting oxidative stress, mitochondrial dysfunction, and amyloid-\u03b2 aggregation. Front Pharmacol [Internet]. 2025;Volume 16\u20132025. https:\/\/www.frontiersin.org\/journals\/pharmacology\/articles\/10.3389\/fphar.2025.1593264.","DOI":"10.3389\/fphar.2025.1593264"},{"key":"3316_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40263-024-01093-0","volume":"38","author":"A Guck\u00fd","year":"2024","unstructured":"Guck\u00fd A, Hamu\u013eakov\u00e1 S. Targeting Biometals in Alzheimer\u2019s Disease with Metal Chelating Agents Including Coumarin Derivatives. CNS Drugs [Internet]. 2024;38:507\u201332. https:\/\/doi.org\/10.1007\/s40263-024-01093-0.","journal-title":"CNS Drugs [Internet]"},{"key":"3316_CR45","doi-asserted-by":"publisher","first-page":"105716","DOI":"10.1016\/j.jddst.2024.105716","volume":"96","author":"A Malaiya","year":"2024","unstructured":"Malaiya A, Kenwat R, Mamgain A, Paliwal SR, Sulakhiya K, Maiti S, et al. QbD-based optimization and evaluation of chitosan-adorned nanostructured lipid carriers for nose-to-brain delivery of 17\u03b2-Estradiol in rat model of Alzheimer\u2019s disease. J Drug Deliv Sci Technol. 2024;96:105716. https:\/\/doi.org\/10.1016\/j.jddst.2024.105716.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3316_CR46","doi-asserted-by":"publisher","unstructured":"Shimohama S, Kawamata J. Roles of Nicotinic Acetylcholine Receptors in the Pathology and Treatment of Alzheimer\u2019s and Parkinson\u2019s Diseases. In: Akaike A, Shimohama S, Misu Y, editors. Nicotinic Acetylcholine Recept Signal Neuroprotection [Internet]. Singapore: Springer Singapore; 2018. p. 137\u201358.  https:\/\/doi.org\/10.1007\/978-981-10-8488-1_8.","DOI":"10.1007\/978-981-10-8488-1_8"},{"key":"3316_CR47","doi-asserted-by":"publisher","unstructured":"Kuo Y-C, Rajesh R. Challenges in the treatment of Alzheimer\u2019s disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors. Expert Rev Neurother [Internet]. Taylor & Francis. 2019;19:623\u201352. https:\/\/doi.org\/10.1080\/14737175.2019.1621750.","DOI":"10.1080\/14737175.2019.1621750"},{"key":"3316_CR48","doi-asserted-by":"publisher","unstructured":"Liu L, He H, Du B, He Y. Nanoscale drug formulations for the treatment of Alzheimer\u2019s disease progression. RSC Adv [Internet].  Royal Soc Chem. 2025;15:4031\u201378. https:\/\/doi.org\/10.1039\/D4RA08128E.","DOI":"10.1039\/D4RA08128E"},{"key":"3316_CR49","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s11671-025-04276-w","volume":"20","author":"SA Khan","year":"2025","unstructured":"Khan SA, Qamar Z, Kamboj S, Moonis M, Rai G, Dang S, et al. Nose to brain delivery of nanostructured lipid carriers loaded with rivastigmine and nilotinib for treating Alzheimer\u2019s disease: preparation, cell line study, and in vivo evaluation. Discov Nano. 2025;20:93. https:\/\/doi.org\/10.1186\/s11671-025-04276-w.","journal-title":"Discov Nano"},{"key":"3316_CR50","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.rechem.2024.101463","volume":"7","author":"A Puri","year":"2024","unstructured":"Puri A, Mohite P, Khan S, Singh S. Breaking the barriers in management of Alzheimer\u2019s disease through cationic nanoformulation: a review. Results Chem. 2024;7:101463. https:\/\/doi.org\/10.1016\/j.rechem.2024.101463.","journal-title":"Results Chem"},{"key":"3316_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29215131","author":"AM Thawabteh","year":"2024","unstructured":"Thawabteh AM, Ghanem AW, AbuMadi S, Thaher D, Jaghama W, Karaman D, et al. Recent advances in therapeutics for the treatment of Alzheimer\u2019s disease. Molecules. 2024. https:\/\/doi.org\/10.3390\/molecules29215131.","journal-title":"Molecules"},{"key":"3316_CR52","doi-asserted-by":"publisher","unstructured":"Puranik N, Yadav D, Song M. Advancements in the application of nanomedicine in Alzheimer\u2019s disease: a therapeutic perspective. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms241814044.","DOI":"10.3390\/ijms241814044"},{"key":"3316_CR53","doi-asserted-by":"publisher","unstructured":"Gernert M, Feja M. Bypassing the blood\u2013brain barrier: direct intracranial drug delivery in epilepsies. Pharmaceutics. 2020;12. https:\/\/doi.org\/10.3390\/pharmaceutics12121134.","DOI":"10.3390\/pharmaceutics12121134"},{"key":"3316_CR54","doi-asserted-by":"publisher","first-page":"100075","DOI":"10.1016\/j.hsr.2023.100075","volume":"6","author":"M Vohra","year":"2023","unstructured":"Vohra M, Amir M, Sharma A, Wadhwa S. Formulation strategies for nose-to-brain drug delivery in Alzheimer\u2019s disease. Health Sci Rev [Internet]. 2023;6:100075. https:\/\/doi.org\/10.1016\/j.hsr.2023.100075.","journal-title":"Health Sci Rev [Internet]"},{"key":"3316_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2019.03.022","volume":"303","author":"R Kanasty","year":"2019","unstructured":"Kanasty R, Low S, Bhise N, Yang J, Peeke E, Schwarz M, et al. A pharmaceutical answer to nonadherence: once weekly oral memantine for Alzheimer\u2019s disease. J Control Release. 2019;303:34\u201341. https:\/\/doi.org\/10.1016\/j.jconrel.2019.03.022.","journal-title":"J Control Release"},{"key":"3316_CR56","doi-asserted-by":"publisher","first-page":"101321","DOI":"10.1016\/j.jddst.2019.101321","volume":"54","author":"X Han","year":"2019","unstructured":"Han X, Yan J, Ren L, Xue M, Yuan Z, Wang T, et al. Preparation and evaluation of orally disintegrating film containing donepezil for Alzheimer disease. J Drug Deliv Sci Technol. 2019;54:101321. https:\/\/doi.org\/10.1016\/j.jddst.2019.101321.","journal-title":"J Drug Deliv Sci Technol"},{"key":"3316_CR57","doi-asserted-by":"publisher","unstructured":"Varun S, Keerthy HS. Innovative strategies in the formulation and applications of mouth dissolving films for enhanced oral drug delivery. Drug Dev Ind Pharm [Internet]. Taylor & Francis; 2025;51:837\u201346.  https:\/\/doi.org\/10.1080\/03639045.2025.2510581.","DOI":"10.1080\/03639045.2025.2510581"},{"key":"3316_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13071046","author":"L Sutthapitaksakul","year":"2021","unstructured":"Sutthapitaksakul L, Thanawuth K, Dass CR, Sriamornsak P. Optimized taste-masked microparticles for orally disintegrating tablets as a promising dosage form for Alzheimer\u2019s disease patients. Pharmaceutics. 2021. https:\/\/doi.org\/10.3390\/pharmaceutics13071046.","journal-title":"Pharmaceutics"},{"key":"3316_CR59","doi-asserted-by":"publisher","unstructured":"Liew KB, Tan YTF, Peh KK. Taste-masked and affordable donepezil hydrochloride orally disintegrating tablet as promising solution for non-compliance in Alzheimer\u2019s disease patients. Drug Dev Ind Pharm [Internet]. Taylor & Franci. 2015;41:583\u201393. https:\/\/doi.org\/10.3109\/03639045.2014.884130.","DOI":"10.3109\/03639045.2014.884130"},{"key":"3316_CR60","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s12247-023-09743-4","volume":"18","author":"DA Farghaly","year":"2023","unstructured":"Farghaly DA, Afifi SA, Aboelwafa AA, Mohamed MI. Oral dissolving film of Rivastigmine: optimization using factorial design. J Pharm Innov. 2023;18:1892\u2013907. https:\/\/doi.org\/10.1007\/s12247-023-09743-4.","journal-title":"J Pharm Innov"},{"key":"3316_CR61","doi-asserted-by":"publisher","unstructured":"Basilicata M, Grillo P, Tancredi A, Di Fiore A, Bollero P, Stefani A, et al. Oral health and use of novel transbuccal drug delivery systems in patients with Alzheimer\u2019s and Parkinson\u2019s disease: a review. Appl Sci. 2023;13. https:\/\/doi.org\/10.3390\/app13084974.","DOI":"10.3390\/app13084974"},{"key":"3316_CR62","doi-asserted-by":"publisher","unstructured":"Radmard A, Banga AK. Development of a hydrophilic transdermal patch for combined delivery of sumatriptan and metoclopramide in migraine therapy. Drug Deliv Transl Res [Internet]. 2025. https:\/\/doi.org\/10.1007\/s13346-025-01874-0.","DOI":"10.1007\/s13346-025-01874-0"},{"key":"3316_CR63","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2174\/1567205019666220823105059","volume":"19","author":"B Schurad","year":"2022","unstructured":"Schurad B, Koch C, Schug B, Morte A, Vaqu\u00e9 A, la De Torre R, et al. Comparative bioavailability study of a novel multi-day patch formulation of rivastigmine (twice weekly) with Exelon\u00ae transdermal patch (daily)- a randomized clinical trial. Curr Alzheimer Res. 2022;19:541\u201353. https:\/\/doi.org\/10.2174\/1567205019666220823105059.","journal-title":"Curr Alzheimer Res"},{"key":"3316_CR64","doi-asserted-by":"publisher","unstructured":"Adler G, Mueller B, Articus K. The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer\u2019s disease under daily practice conditions. Int J Clin Pract [Internet]. John Wiley & Sons, Ltd; 2014 [cited 2025 Aug 30];68:465\u201370. https:\/\/doi.org\/10.1111\/ijcp.12374.","DOI":"10.1111\/ijcp.12374"},{"key":"3316_CR65","doi-asserted-by":"publisher","unstructured":"Kumar A, Sudevan ST, Nair AS, Singh AK, Kumar S, Jose J, et al. Current and future nano-carrier-based approaches in the treatment of Alzheimer\u2019s disease. Brain Sci. 2023;13. https:\/\/doi.org\/10.3390\/brainsci13020213.","DOI":"10.3390\/brainsci13020213"},{"key":"3316_CR66","doi-asserted-by":"publisher","unstructured":"Rehman NU, Song C, Kim J, Noh I, Rhee Y-S, Chung HJ. Pharmacokinetic Evaluation of a Novel Donepezil-Loaded Dissolving Microneedle Patch in Rats. Pharmaceutics. 2022;14.  https:\/\/doi.org\/10.3390\/pharmaceutics14010005.","DOI":"10.3390\/pharmaceutics14010005"},{"key":"3316_CR67","doi-asserted-by":"publisher","unstructured":"Monou P-K, Andriotis EG, Saropoulou E, Tzimtzimis E, Tzetzis D, Komis G, et al. Fabrication of hybrid coated microneedles with donepezil utilizing digital light processing and semisolid extrusion printing for the management of Alzheimer\u2019s disease. Mol Pharm [Internet]. Am Chem Soc. 2024;21:4450\u201364. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00377.","DOI":"10.1021\/acs.molpharmaceut.4c00377"},{"key":"3316_CR68","doi-asserted-by":"publisher","unstructured":"Shin GR, Kim HE, Kim JH, Choi S, Kim MS. Advances in injectable in situ-forming hydrogels for intratumoral treatment. Pharmaceutics. 2021;13. https:\/\/doi.org\/10.3390\/pharmaceutics13111953.","DOI":"10.3390\/pharmaceutics13111953"},{"key":"3316_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-2757-6","volume":"37","author":"L Lipp","year":"2020","unstructured":"Lipp L, Sharma D, Banerjee A, Singh J. In vitro and in vivo optimization of phase sensitive smart polymer for controlled delivery of rivastigmine for treatment of Alzheimer\u2019s Disease. Pharm Res. 2020;37: 34. https:\/\/doi.org\/10.1007\/s11095-020-2757-6.","journal-title":"Pharm Res"},{"key":"3316_CR70","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3923\/ijp.2019.124.128","volume":"15","author":"HM Alkhalidi","year":"2019","unstructured":"Alkhalidi HM, Mouminah AS. In vivo evaluation of galantamine injectable in situ gel for management of Alzheimer\u2019s Disease in controlled manner. IJP. 2019;15:124\u20138.","journal-title":"IJP"},{"key":"3316_CR71","doi-asserted-by":"publisher","unstructured":"Huang Q, Chen X, Yu S, Gong G, Shu H. Research progress in brain-targeted nasal drug delivery. Front Aging Neurosci [Internet]. 2024;15\u20132023. https:\/\/doi.org\/10.3389\/fnagi.2023.1341295.","DOI":"10.3389\/fnagi.2023.1341295"},{"key":"3316_CR72","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-025-03171-y","volume":"26","author":"S Lobo","year":"2025","unstructured":"Lobo S, Xi Z, Das D, Hadzimichalis NM, Creek JA. Intranasal delivery: formulation factors and insights into user experience. AAPS PharmSciTech. 2025;26: 179. https:\/\/doi.org\/10.1208\/s12249-025-03171-y.","journal-title":"AAPS PharmSciTech"},{"key":"3316_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.123809","volume":"652","author":"H Guo","year":"2024","unstructured":"Guo H, Wang G, Zhai Z, Huang J, Huang Z, Zhou Y, et al. Rivastigmine nasal spray for the treatment of Alzheimer\u2019s Disease: olfactory deposition and brain delivery. Int J Pharm. 2024;652: 123809. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.123809.","journal-title":"Int J Pharm"},{"key":"3316_CR74","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijpharm.2014.04.015","volume":"468","author":"S Qian","year":"2014","unstructured":"Qian S, Wong YC, Zuo Z. Development, characterization and application of in situ gel systems for intranasal delivery of tacrine. Int J Pharm. 2014;468:272\u201382. https:\/\/doi.org\/10.1016\/j.ijpharm.2014.04.015.","journal-title":"Int J Pharm"},{"key":"3316_CR75","doi-asserted-by":"publisher","unstructured":"Papakyriakopoulou P, Rekkas DM, Colombo G, Valsami G. Development and in vitro-ex vivo evaluation of novel polymeric nasal donepezil films for potential use in Alzheimer\u2019s disease using experimental design. Pharmaceutics. 2022;14. https:\/\/doi.org\/10.3390\/pharmaceutics14081742.","DOI":"10.3390\/pharmaceutics14081742"},{"key":"3316_CR76","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040481","author":"S Gandhi","year":"2024","unstructured":"Gandhi S, Shastri DH, Shah J, Nair AB, Jacob S. Nasal delivery to the brain: harnessing nanoparticles for effective drug transport. Pharmaceutics. 2024. https:\/\/doi.org\/10.3390\/pharmaceutics16040481.","journal-title":"Pharmaceutics"},{"key":"3316_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01915-3","volume":"29","author":"I Iqbal","year":"2024","unstructured":"Iqbal I, Saqib F, Mubarak Z, Latif MF, Wahid M, Nasir B, et al. Alzheimer\u2019s disease and drug delivery across the blood\u2013brain barrier: approaches and challenges. Eur J Med Res. 2024;29: 313. https:\/\/doi.org\/10.1186\/s40001-024-01915-3.","journal-title":"Eur J Med Res"},{"key":"3316_CR78","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/10717544.2018.1428243","volume":"25","author":"G Karthivashan","year":"2018","unstructured":"Karthivashan G, Ganesan P, Park S-Y, Kim J-S, Choi D-K. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer\u2019s disease. Drug Deliv. 2018;25:307\u201320. https:\/\/doi.org\/10.1080\/10717544.2018.1428243.","journal-title":"Drug Deliv"},{"key":"3316_CR79","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jconrel.2023.02.024","volume":"356","author":"YB Ji","year":"2023","unstructured":"Ji YB, Lee S, Ju HJ, Kim HE, Noh JH, Choi S, et al. Preparation and evaluation of injectable microsphere formulation for longer sustained release of donepezil. J Control Release. 2023;356:43\u201358. https:\/\/doi.org\/10.1016\/j.jconrel.2023.02.024.","journal-title":"J Control Release"},{"key":"3316_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2021.111721","volume":"203","author":"IFF de Souza","year":"2021","unstructured":"de Souza IFF, dos Santos TQ, Placido RV, Mangerona BA, Carvalho FC, Boralli VB, et al. The liquid crystalline phase behaviour of a nasal formulation modifies the brain disposition of donepezil in rats in the treatment of Alzheimer\u2019s disease. Colloids Surf B Biointerfaces. 2021;203: 111721. https:\/\/doi.org\/10.1016\/j.colsurfb.2021.111721.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3316_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2025.114909","volume":"255","author":"M-H Fathian-Nasab","year":"2025","unstructured":"Fathian-Nasab M-H, Manavi M-A, Gelivarisarshari M, Daghighi S-M, Beyer C, Baeeri M, et al. Unveiling the hidden risks of human exposure to nanomedicine and nanopollutants: nanoparticle-induced blood barrier disruption and tissue toxicity. Colloids Surf B Biointerfaces. 2025;255: 114909. https:\/\/doi.org\/10.1016\/j.colsurfb.2025.114909.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3316_CR82","doi-asserted-by":"publisher","unstructured":"Shivananjegowda MG, Hani U, Osmani RAM, Alamri AH, Ghazwani M, Alhamhoom Y, et al. Development and evaluation of solid lipid nanoparticles for the clearance of A\u03b2 in Alzheimer\u2019s disease. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15010221.","DOI":"10.3390\/pharmaceutics15010221"},{"key":"3316_CR83","doi-asserted-by":"publisher","first-page":"300","DOI":"10.3109\/1061186X.2012.747529","volume":"21","author":"M Yusuf","year":"2013","unstructured":"Yusuf M, Khan M, Khan RA, Ahmed B. Preparation, characterization, in vivo and biochemical evaluation of brain targeted Piperine solid lipid nanoparticles in an experimentally induced Alzheimer\u2019s disease model. J Drug Target [Internet]. 2013;21:300\u201311. https:\/\/doi.org\/10.3109\/1061186X.2012.747529.","journal-title":"J Drug Target [Internet]"},{"key":"3316_CR84","doi-asserted-by":"publisher","first-page":"710","DOI":"10.2174\/0115672050288659240229080535","volume":"21","author":"A Tekade","year":"2024","unstructured":"Tekade A, Susar R, Kulkarni G, Surwade S, Gaikwad A. Nanostructured Lipid Carriers of Donepezil Hydrochloride for the Treatment of Alzheimer\u2019s Disease. Curr Alzheimer Res [Internet]. 2024;21:710\u201322. https:\/\/doi.org\/10.2174\/0115672050288659240229080535.","journal-title":"Curr Alzheimer Res [Internet]"},{"key":"3316_CR85","doi-asserted-by":"publisher","first-page":"122167","DOI":"10.1016\/j.ijpharm.2022.122167","volume":"626","author":"S Andrade","year":"2022","unstructured":"Andrade S, Ramalho MJ, Loureiro JA, Pereira MC. Transferrin-functionalized liposomes loaded with vitamin VB12 for Alzheimer\u2019s disease therapy. Int J Pharm. 2022;626:122167. https:\/\/doi.org\/10.1016\/j.ijpharm.2022.122167.","journal-title":"Int J Pharm"},{"key":"3316_CR86","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijpharm.2013.05.009","volume":"452","author":"Z-Z Yang","year":"2013","unstructured":"Yang Z-Z, Zhang Y-Q, Wang Z-Z, Wu K, Lou J-N, Qi X-R. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration. Int J Pharm. 2013;452:344\u201354. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.05.009.","journal-title":"Int J Pharm"},{"key":"3316_CR87","doi-asserted-by":"publisher","unstructured":"Turkez H, Oner S, Y\u0131ld\u0131r\u0131m OC, Arslan ME, Dimmito MP, Kahraman \u00c7Y, et al. Synthesis and characterization of Memantine-Loaded niosomes for enhanced Alzheimer\u2019s disease targeting. Pharmaceutics. 2025;17. https:\/\/doi.org\/10.3390\/pharmaceutics17020267.","DOI":"10.3390\/pharmaceutics17020267"},{"key":"3316_CR88","doi-asserted-by":"publisher","first-page":"104","DOI":"10.22037\/ipa.v1i1.19964","volume":"1","author":"MA Raeisi Estabragh","year":"2018","unstructured":"Raeisi Estabragh MA, Hamidifar Z, Pardakhty A. Formulation of Rivastigmine niosomes for Alzheimer disease. International Pharmacy Acta. 2018;1:104. https:\/\/doi.org\/10.22037\/ipa.v1i1.19964.","journal-title":"International Pharmacy Acta"},{"key":"3316_CR89","doi-asserted-by":"publisher","unstructured":"Rajendran A, Elumalai V, Balasubramaniyam S, Elumalai K. Transferosome formulations as innovative carriers for transdermal drug delivery: composition, properties, and therapeutic applications. Biomed Mater Devices [Internet]. 2025. https:\/\/doi.org\/10.1007\/s44174-024-00269-y.","DOI":"10.1007\/s44174-024-00269-y"},{"key":"3316_CR90","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1016\/j.xphs.2024.02.014","volume":"113","author":"HF Salem","year":"2024","unstructured":"Salem HF, Aboud HM, Abdellatif MM, Abou-Taleb HA. Nose-to-brain targeted delivery of donepezil hydrochloride via novel hyaluronic acid-doped nanotransfersomes for Alzheimer\u2019s disease mitigation. J Pharm Sci. 2024;113:1934\u201345. https:\/\/doi.org\/10.1016\/j.xphs.2024.02.014.","journal-title":"J Pharm Sci"},{"key":"3316_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-024-00742-w","volume":"25","author":"J Wu","year":"2024","unstructured":"Wu J, Xu R, Xu X, Ye S, Huang A. Preparation and evaluation of transdermal permeation of Huperzine A ethosomes gel in vitro. BMC Pharmacol Toxicol. 2024;25: 21. https:\/\/doi.org\/10.1186\/s40360-024-00742-w.","journal-title":"BMC Pharmacol Toxicol"},{"key":"3316_CR92","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/02652048.2025.2500542","volume":"42","author":"MM Farag","year":"2025","unstructured":"Farag MM, Abdelmalak NS, El Menshawe SF, Omara AS, Hamad DS. Repurposing linagliptin-loaded novasomes as a neuroprotectant for Alzheimer\u2019s disease: in-vitro characterisation, statistical optimisation and ex-vivo permeation study. J Microencapsul. 2025;42:531\u201345. https:\/\/doi.org\/10.1080\/02652048.2025.2500542.","journal-title":"J Microencapsul"},{"key":"3316_CR93","doi-asserted-by":"publisher","unstructured":"Kandeil MA, Mohammed ET, Ibrahim MA, Radi RA, Gamal A, Abdel-Razik A-RH, et al. Formulation and evaluation of astaxanthin-loaded invasomes as therapeutic approaches for Alzheimer\u2019s disease induced in rats: role of SIRT-1\/BDNF\/miRNA-134\/GSK-3\u03b2 signaling. Mol Neurobiol. 2025. https:\/\/doi.org\/10.1007\/s12035-025-05241-5.","DOI":"10.1007\/s12035-025-05241-5"},{"key":"3316_CR94","doi-asserted-by":"publisher","unstructured":"Elsheikh MA, El-Feky YA, Al-Sawahli MM, Ali ME, Fayez AM, Abbas H. A brain-targeted approach to ameliorate memory disorders in a sporadic Alzheimer\u2019s disease mouse model via intranasal luteolin-loaded nanobilosomes. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14030576.","DOI":"10.3390\/pharmaceutics14030576"},{"key":"3316_CR95","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.2147\/IJN.S87336","volume":"10","author":"YS Elnaggar","year":"2015","unstructured":"Elnaggar YS, Etman SM, bdelmonsif DA, Abdallah OY. Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer\u2019s disease: pharmaceutical, biological, and toxicological studies. Int J Nanomedicine. 2015;10:5459\u201373. https:\/\/doi.org\/10.2147\/IJN.S87336.","journal-title":"Int J Nanomedicine"},{"key":"3316_CR96","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/10717544.2020.1762262","volume":"27","author":"Y Qi","year":"2020","unstructured":"Qi Y, Guo L, Jiang Y, Shi Y, Sui H, Zhao L. Brain delivery of quercetin-loaded exosomes improved cognitive function in AD mice by inhibiting phosphorylated tau-mediated neurofibrillary tangles. Drug Deliv. 2020;27:745\u201355. https:\/\/doi.org\/10.1080\/10717544.2020.1762262.","journal-title":"Drug Deliv"},{"key":"3316_CR97","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/09205063.2022.2088527","volume":"33","author":"N Vasdev","year":"2022","unstructured":"Vasdev N, Handa M, Kesharwani P, Shukla R. Rosemary oil low energy nanoemulsion: optimization, \u00b5rheology, in silico, in\u00a0vitro, and ex vivo characterization. J Biomater Sci Polym Ed. 2022;33:1901\u201323. https:\/\/doi.org\/10.1080\/09205063.2022.2088527.","journal-title":"J Biomater Sci Polym Ed"},{"key":"3316_CR98","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11101986","author":"NK Alaqeel","year":"2022","unstructured":"Alaqeel NK, AlSheikh MH, Al-Hariri MT. Quercetin nanoemulsion ameliorates neuronal dysfunction in experimental Alzheimer\u2019s disease model. Antioxidants. 2022. https:\/\/doi.org\/10.3390\/antiox11101986.","journal-title":"Antioxidants"},{"key":"3316_CR99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119725","volume":"588","author":"AC Sintov","year":"2020","unstructured":"Sintov AC. AmyloLipid nanovesicles: a self-assembled lipid-modified starch hybrid system constructed for direct nose-to-brain delivery of curcumin. Int J Pharm. 2020;588: 119725. https:\/\/doi.org\/10.1016\/j.ijpharm.2020.119725.","journal-title":"Int J Pharm"},{"key":"3316_CR100","doi-asserted-by":"publisher","first-page":"102048","DOI":"10.1016\/j.jsps.2024.102048","volume":"32","author":"F Imam","year":"2024","unstructured":"Imam F, Mukhopadhyay S, Kothiyal P, Alshehri S, Saad Alharbi K, Afzal M, et al. Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer\u2019s disease. Saudi Pharm J. 2024;32:102048. https:\/\/doi.org\/10.1016\/j.jsps.2024.102048.","journal-title":"Saudi Pharm J"},{"key":"3316_CR101","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12951-018-0356-z","volume":"16","author":"E S\u00e1nchez-L\u00f3pez","year":"2018","unstructured":"S\u00e1nchez-L\u00f3pez E, Ettcheto M, Egea MA, Espina M, Cano A, Calpena AC, et al. Memantine loaded PLGA PEGylated nanoparticles for Alzheimer\u2019s disease: in vitro and in vivo characterization. J Nanobiotechnology. 2018;16:32. https:\/\/doi.org\/10.1186\/s12951-018-0356-z.","journal-title":"J Nanobiotechnology"},{"key":"3316_CR102","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-95792-3","volume":"15","author":"M K\u00f6m\u00fcr","year":"2025","unstructured":"K\u00f6m\u00fcr M, K\u0131yan HT, \u00d6zt\u00fcrk AA. Development of donepezil hydrochloride-loaded PLGA-based nanoparticles for Alzheimer\u2019s disease treatment. Sci Rep. 2025;15: 13184. https:\/\/doi.org\/10.1038\/s41598-025-95792-3.","journal-title":"Sci Rep"},{"key":"3316_CR103","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/1061186X.2020.1817041","volume":"29","author":"S Zameer","year":"2021","unstructured":"Zameer S, Ali J, Vohora D, Najmi AK, Akhtar M. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer\u2019s disease in intracerebroventricular streptozotocin model for brain delivery. J Drug Target. 2021;29:199\u2013216. https:\/\/doi.org\/10.1080\/1061186X.2020.1817041.","journal-title":"J Drug Target"},{"key":"3316_CR104","doi-asserted-by":"publisher","unstructured":"Savall AS, de Mello JD, Fidelis EM, Comis-Neto AA, Nepomuceno MR, Pacheco CD, et al. Nanoencapsulated Curcumin: enhanced efficacy in reversing memory loss in an alzheimer disease model. Brain Sci. 2024;14. https:\/\/doi.org\/10.3390\/brainsci14020130.","DOI":"10.3390\/brainsci14020130"},{"key":"3316_CR105","doi-asserted-by":"publisher","first-page":"e0235979","DOI":"10.1371\/journal.pone.0235979","volume":"15","author":"N Tanaka","year":"2020","unstructured":"Tanaka N, Okuda M, Nishigaki T, Tsuchiya N, Kobayashi Y, Uemura T, et al. Development of a brain-permeable peptide nanofiber that prevents aggregation of Alzheimer pathogenic proteins. PLoS ONE. 2020;15:e0235979. https:\/\/doi.org\/10.1371\/journal.pone.0235979.","journal-title":"PLoS ONE"},{"key":"3316_CR106","doi-asserted-by":"publisher","unstructured":"Gothwal A, Kumar H, Nakhate KT, Ajazuddin, Dutta A, Borah A, et al. Lactoferrin Coupled Lower Generation PAMAM Dendrimers for Brain Targeted Delivery of Memantine in Aluminum-Chloride-Induced Alzheimer\u2019s Disease in Mice. Bioconjug Chem [Internet]. Am Chem Soc. 2019;30:2573\u201383.  https:\/\/doi.org\/10.1021\/acs.bioconjchem.9b00505.","DOI":"10.1021\/acs.bioconjchem.9b00505"},{"key":"3316_CR107","doi-asserted-by":"publisher","unstructured":"Sahiner M, Suner SS, Sahiner N. AChE inhibition capability of nanogels derived from natural molecules: tannic acid and lysine for Alzheimer\u2019s disease. Pharmaceutics. 2025. https:\/\/doi.org\/10.3390\/pharmaceutics17040502.","DOI":"10.3390\/pharmaceutics17040502"},{"key":"3316_CR108","doi-asserted-by":"publisher","first-page":"101406","DOI":"10.1016\/j.nanoso.2024.101406","volume":"40","author":"T Garg","year":"2024","unstructured":"Garg T, Patel S, Yadav D, Dave V, Yadav R. Enhanced delivery of rivastigmine for Alzheimer\u2019s disease: Convolvulus pluricaulis lipid hybrid nanoparticles. Nano-Struct Nano-Objects. 2024;40:101406. https:\/\/doi.org\/10.1016\/j.nanoso.2024.101406.","journal-title":"Nano-Struct Nano-Objects"},{"key":"3316_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101347","volume":"29","author":"J Zhang","year":"2024","unstructured":"Zhang J, Yang X, Wang S, Dong J, Zhang M, Zhang M, et al. Metformin carbon dots enhance neurogenesis and neuroprotection in Alzheimer\u2019s disease: a potential nanomedicine approach. Materials Today Bio. 2024;29: 101347. https:\/\/doi.org\/10.1016\/j.mtbio.2024.101347.","journal-title":"Materials Today Bio"},{"key":"3316_CR110","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ijpharm.2017.07.080","volume":"530","author":"S Lohan","year":"2017","unstructured":"Lohan S, Raza K, Mehta SK, Bhatti GK, Saini S, Singh B. Anti-Alzheimer\u2019s potential of berberine using surface decorated multi-walled carbon nanotubes: a preclinical evidence. Int J Pharm. 2017;530:263\u201378. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.07.080.","journal-title":"Int J Pharm"},{"key":"3316_CR111","doi-asserted-by":"publisher","unstructured":"Mazyed EA, Helal DA, Elkhoudary MM, Abd Elhameed AG, Yasser M. Formulation and optimization of nanospanlastics for improving the bioavailability of green tea epigallocatechin gallate. Pharmaceuticals. 2021;14. https:\/\/doi.org\/10.3390\/ph14010068.","DOI":"10.3390\/ph14010068"},{"key":"3316_CR112","doi-asserted-by":"publisher","unstructured":"Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH. Protein-based nanoparticles as drug delivery systems. Pharmaceutics. 2020. https:\/\/doi.org\/10.3390\/pharmaceutics12070604.","DOI":"10.3390\/pharmaceutics12070604"},{"key":"3316_CR113","doi-asserted-by":"publisher","DOI":"10.1186\/s11671-018-2759-z","volume":"13","author":"R Yang","year":"2018","unstructured":"Yang R, Zheng Y, Wang Q, Zhao L. Curcumin-loaded chitosan\u2013bovine serum albumin nanoparticles potentially enhanced A\u03b2 42 phagocytosis and modulated macrophage polarization in Alzheimer\u2019s disease. Nanoscale Res Lett. 2018;13: 330. https:\/\/doi.org\/10.1186\/s11671-018-2759-z.","journal-title":"Nanoscale Res Lett"},{"key":"3316_CR114","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/jphp.12836","volume":"70","author":"LR Wong","year":"2018","unstructured":"Wong LR, Ho PC. Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer\u2019s disease. J Pharm Pharmacol. 2018;70:59\u201369. https:\/\/doi.org\/10.1111\/jphp.12836.","journal-title":"J Pharm Pharmacol"},{"key":"3316_CR115","doi-asserted-by":"publisher","unstructured":"Sivanesan S, Shanmugam R. Gold Nanoparticles in Diagnosis and Treatment of Alzheimer\u2019s Disease. 2019. p. 289\u2013306. https:\/\/doi.org\/10.1007\/978-3-030-30930-5_12.","DOI":"10.1007\/978-3-030-30930-5_12"},{"key":"3316_CR116","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.msec.2017.03.283","volume":"77","author":"AP Muller","year":"2017","unstructured":"Muller AP, Ferreira GK, Pires AJ, de Bem Silveira G, de Souza DL, Brandolfi JdeA, et al. Gold nanoparticles prevent cognitive deficits, oxidative stress and inflammation in a rat model of sporadic dementia of Alzheimer\u2019s type. Mater Sci Eng, C. 2017;77:476\u201383. https:\/\/doi.org\/10.1016\/j.msec.2017.03.283.","journal-title":"Mater Sci Eng, C"},{"key":"3316_CR117","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ijbiomac.2019.09.098","volume":"142","author":"F Gao","year":"2020","unstructured":"Gao F, Zhao J, Liu P, Ji D, Zhang L, Zhang M, et al. Preparation and in vitro evaluation of multi-target-directed selenium-chondroitin sulfate nanoparticles in protecting against the Alzheimer\u2019s disease. Int J Biol Macromol. 2020;142:265\u201376. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.09.098.","journal-title":"Int J Biol Macromol"},{"key":"3316_CR118","doi-asserted-by":"publisher","unstructured":"Danish SM, Gupta A, Khan UA, Hasan N, Ahmad FJ, Warsi MH, et al. Intranasal cerium oxide nanoparticles ameliorate cognitive function in rats with Alzheimer\u2019s via anti-oxidative pathway. Pharmaceutics. 2022;14. https:\/\/doi.org\/10.3390\/pharmaceutics14040756.","DOI":"10.3390\/pharmaceutics14040756"},{"key":"3316_CR119","doi-asserted-by":"publisher","first-page":"265","DOI":"10.14283\/jpad.2024.37","volume":"11","author":"AC Bradshaw","year":"2024","unstructured":"Bradshaw AC, Georges J. Anti-amyloid therapies for Alzheimer\u2019s disease: an Alzheimer Europe position paper and call to action. J Prev Alzheimers Dis. 2024;11:265\u201373. https:\/\/doi.org\/10.14283\/jpad.2024.37.","journal-title":"J Prev Alzheimers Dis"},{"key":"3316_CR120","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/cts.12755","volume":"13","author":"AV Morant","year":"2020","unstructured":"Morant AV, Vestergaard HT, Lassen AB, Navikas V. US, EU, and Japanese regulatory guidelines for development of drugs for treatment of Alzheimer\u2019s disease: implications for global drug development. Clin Transl Sci. 2020;13:652\u201364. https:\/\/doi.org\/10.1111\/cts.12755.","journal-title":"Clin Transl Sci"},{"key":"3316_CR121","doi-asserted-by":"publisher","unstructured":"Dighe S, Jog S, Momin M, Sawarkar S, Omri A. Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer\u2019s Disease Management. Pharmaceutics. 2024;16.  https:\/\/doi.org\/10.3390\/pharmaceutics16010058.","DOI":"10.3390\/pharmaceutics16010058"},{"key":"3316_CR122","doi-asserted-by":"publisher","first-page":"e70131","DOI":"10.1002\/prp2.70131","volume":"13","author":"MS Hossain","year":"2025","unstructured":"Hossain MS, Hussain MH. Multi-target drug design in Alzheimer\u2019s disease treatment: emerging technologies, advantages, challenges, and limitations. Pharmacol Res Perspect. 2025;13:e70131. https:\/\/doi.org\/10.1002\/prp2.70131.","journal-title":"Pharmacol Res Perspect"},{"key":"3316_CR123","doi-asserted-by":"publisher","unstructured":"Gabel M, Bekena S, O\u2019Meara M, Denny A, Solomon ED, Moulder KL, et al. Current practices by Alzheimer\u2019s Disease Research Centers to remunerate research participants. Alzheimers Dement [Internet]. John Wiley & Sons, Ltd; 2025 [cited 2025 Nov 3];21:e14542.  https:\/\/doi.org\/10.1002\/alz.14542.","DOI":"10.1002\/alz.14542"},{"key":"3316_CR124","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/idm2.12050","volume":"1","author":"J Jin","year":"2022","unstructured":"Jin J, Yang L, Chen F, Gu N. Drug delivery system based on nanobubbles. Interdiscip Mater. 2022;1:471\u201394. https:\/\/doi.org\/10.1002\/idm2.12050.","journal-title":"Interdiscip Mater"},{"key":"3316_CR125","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s10072-025-08073-2","volume":"46","author":"I Serag","year":"2025","unstructured":"Serag I, Abouzid M, Moawad MHED, Jaradat JH, Hendawy M, Hendi NI, et al. Vaccines for Alzheimer\u2019s disease: a brief scoping review. Neurol Sci [Internet]. 2025;46:2925\u201350. https:\/\/doi.org\/10.1007\/s10072-025-08073-2.","journal-title":"Neurol Sci [Internet]"},{"key":"3316_CR126","doi-asserted-by":"publisher","unstructured":"Ou C-M, Xue W-W, Liu D, Ma L, Xie H-T, Ning K. Stem cell therapy in Alzheimer\u2019s disease: current status and perspectives. Front Neurosci [Internet]. 2024;18\u20132024. https:\/\/doi.org\/10.3389\/fnins.2024.1440334.","DOI":"10.3389\/fnins.2024.1440334"},{"key":"3316_CR127","doi-asserted-by":"publisher","first-page":"S433","DOI":"10.3233\/JAD-240545","volume":"101","author":"MH Tuszynski","year":"2024","unstructured":"Tuszynski MH. Growth factor gene therapy for Alzheimer\u2019s disease. J Alzheimers Dis. 2024;101:S433\u201341. https:\/\/doi.org\/10.3233\/JAD-240545.","journal-title":"J Alzheimers Dis"},{"key":"3316_CR128","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijpharm.2013.11.049","volume":"461","author":"C Zhang","year":"2014","unstructured":"Zhang C, Chen J, Feng C, Shao X, Liu Q, Zhang Q, et al. Intranasal nanoparticles of basic fibroblast growth factor for brain delivery to treat Alzheimer\u2019s disease. Int J Pharm. 2014;461:192\u2013202. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.11.049.","journal-title":"Int J Pharm"},{"key":"3316_CR129","doi-asserted-by":"publisher","first-page":"102193","DOI":"10.1016\/j.jsps.2024.102193","volume":"32","author":"K Huanbutta","year":"2024","unstructured":"Huanbutta K, Puri V, Sharma A, Singh I, Sriamornsak P, Sangnim T. Rise of implantable drugs: a chronicle of breakthroughs in drug delivery systems. Saudi Pharm J. 2024;32:102193. https:\/\/doi.org\/10.1016\/j.jsps.2024.102193.","journal-title":"Saudi Pharm J"},{"key":"3316_CR130","doi-asserted-by":"publisher","first-page":"102497","DOI":"10.1016\/j.arr.2024.102497","volume":"101","author":"M Kale","year":"2024","unstructured":"Kale M, Wankhede N, Pawar R, Ballal S, Kumawat R, Goswami M, et al. AI-driven innovations in Alzheimer\u2019s disease: integrating early diagnosis, personalized treatment, and prognostic modelling. Ageing Res Rev. 2024;101:102497. https:\/\/doi.org\/10.1016\/j.arr.2024.102497.","journal-title":"Ageing Res Rev"},{"key":"3316_CR131","doi-asserted-by":"publisher","unstructured":"Song S, Li T, Lin W, Liu R, Zhang Y. Application of artificial intelligence in Alzheimer\u2019s disease: a bibliometric analysis. Front Neurosci [Internet]. 2025;19\u20132025. https:\/\/doi.org\/10.3389\/fnins.2025.1511350.","DOI":"10.3389\/fnins.2025.1511350"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03316-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-025-03316-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-025-03316-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T18:05:06Z","timestamp":1770314706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-025-03316-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3316"],"URL":"https:\/\/doi.org\/10.1208\/s12249-025-03316-z","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"21 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author declares no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"78"}}